StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT - Free Report) in a report released on Wednesday morning. The firm issued a hold rating on the stock.
Several other analysts also recently issued reports on the company. JMP Securities reiterated a "market outperform" rating and issued a $5.00 price target on shares of DBV Technologies in a report on Tuesday, September 24th. HC Wainwright boosted their price target on DBV Technologies from $5.00 to $7.00 and gave the stock a "buy" rating in a research report on Thursday, October 24th.
Check Out Our Latest Report on DBVT
DBV Technologies Price Performance
NASDAQ DBVT traded up $0.01 during mid-day trading on Wednesday, hitting $0.77. The company's stock had a trading volume of 66,523 shares, compared to its average volume of 234,774. DBV Technologies has a 52-week low of $0.50 and a 52-week high of $2.14. The stock's fifty day simple moving average is $0.75 and its two-hundred day simple moving average is $0.92. The firm has a market capitalization of $74.31 million, a P/E ratio of -0.83 and a beta of 0.66.
Hedge Funds Weigh In On DBV Technologies
An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. increased its stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 6.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,568,909 shares of the company's stock after purchasing an additional 327,345 shares during the period. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.'s portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 71.74% of the company's stock.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
